Eribulin mesylate in the treatment of metastatic breast cancer

References

• JemalABrayFCenterMMGlobal cancer statisticsCA Cancer J Clin201161699021296855
   PubMed Web of Science ®Google Scholar
• BrewsterAMHortobagyiGNBroglioKRResidual risk of breast cancer recurrence five years after adjuvant therapyJ Natl Cancer Inst20081001179118318695137
   PubMedGoogle Scholar
• JemalASiegelRXuJCancer statistics, 2010CA Cancer J Clin20106027730020610543
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJMilesDVukeljaSSuperior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial resultsJ Clin Oncol2002202812282312065558
   PubMed Web of Science ®Google Scholar
• ThomasESGomezHLLiRKIxabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentJ Clin Oncol2007255210521717968020
   PubMed Web of Science ®Google Scholar
• SparanoJAVrdoljakERixeORandomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol2010283256326320530276
   PubMed Web of Science ®Google Scholar
• CortesJO’ShaughnessyJLoeschDEribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyLancet201137791492321376385
   PubMed Web of Science ®Google Scholar
• HirataYUemuraDHalichondrins-antitumor polyether macrolides from a marine spongePure Appl Chem198658701710
   Web of Science ®Google Scholar
• BaiRLPaullKDHeraldCLHalichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity dataJ Biol Chem199126615882158891874739
   PubMed Web of Science ®Google Scholar
• TowleMJSalvatoKABudrowJIn vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin BCancer Res2001611013102111221827
   PubMed Web of Science ®Google Scholar
• AicherTDBuszekKRFangFGTotal synthesis of halichondrin B and norhalichondrin BJ Am Chem Soc199211431623164
   Web of Science ®Google Scholar
• JordanMAKamathKMannaTThe primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growthMol Cancer Ther200541086109516020666
   PubMed Web of Science ®Google Scholar
• AldayPHCorreiaJJMacromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugationBiochemistry2009487927793819586046
   PubMed Web of Science ®Google Scholar
• KuznetsovGTenDykeKYuMAntiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitroProc Am Assoc Cancer Res2007C58
   Google Scholar
• KuznetsovGTowleMJChengHInduction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389Cancer Res2004645760576615313917
   PubMed Web of Science ®Google Scholar
• OkounevaTAzarenkoOWilsonLInhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseMol Cancer Ther200872003201118645010
   PubMed Web of Science ®Google Scholar
• SynoldTWMorganRJNewmanEMA Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer consortium trial [abstract 3036]J Clin Oncol200523Suppl3036
   Web of Science ®Google Scholar
• GoelSMitaACMitaMA phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignanciesClin Cancer Res2009154207421219509177
   PubMed Web of Science ®Google Scholar
• TanARRubinEHWaltonDCPhase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumorsClin Cancer Res2009154213421919509146
   PubMed Web of Science ®Google Scholar
• SynoldTTsao-WeiDQuinnDPhase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium Trial [abstract]J Clin Oncol201028Suppl Abst 2527
   Google Scholar
• WitteveenPMarchettiSMergui-RoelvinkMEribulin mesylate pharmacokinetics in patients with hepatic impairment [abstract]J Clin Oncol201028Suppl Abst 2582
   Google Scholar
• ZhangZYKingBMPelletierRDDelineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4Cancer Chemother Pharmacol20086270771618431572
   PubMed Web of Science ®Google Scholar
• DevrieseLWandersJJennerAEribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole [abstract]EORTC-NCI-AACR Symposium20108181 Abst 574
   Google Scholar
• ZhengWSeletskyBPalmeMStructure-activity relationships of synthetic halicondrin B analog E7389: in vitro susceptibility to PgP-mediated drug efflux [abstract]Proc Am Assoc Cancer Res20037 Abst 2751
   Google Scholar
• AgoulnikSKuznetsovGTendykeKSensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with ßIII tubulin isotype expression in human breast cancer cell linesJ Clin Oncol200523201215774792
   PubMed Web of Science ®Google Scholar
• MinamiHMukoharaTNagaiSA phase I study of eribulin mesylate (E7389) in patients with refractory cancersEur J Cancer Suppl20086140
   Web of Science ®Google Scholar
• GoelRChenEWelchSPhase I study of E7389/gemcitabine combination in patients with advanced solid tumors [abstract]J Clin Oncol200927Suppl Abst e13509
   Google Scholar
• SwamiUPetrylakDPRaftopoulosHPhase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors [abstract]J Clin Oncol201028Suppl Abstr 2589
   Google Scholar
• VahdatLTPruittBFabianCJPhase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol2009272954296119349550
   PubMed Web of Science ®Google Scholar
• CortesJVahdatLBlumJLPhase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJ Clin Oncol2010283922392820679609
   PubMed Web of Science ®Google Scholar
• IwataHAogiKMasudaNEfficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer [abstract]J Clin Oncol2010281081
   Web of Science ®Google Scholar
• TwelvesCCortesJVahdatLTPhase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancerClin Breast Cancer20101016016320299316
   PubMed Web of Science ®Google Scholar
• LeeJJSwainSMPeripheral neuropathy induced by microtubule-stabilizing agentsJ Clin Oncol2006241633164216575015
   PubMed Web of Science ®Google Scholar
• WozniakKMNomotoKLapidusRGComparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in miceCancer Res2011713952396221498637
   PubMed Web of Science ®Google Scholar
• www.ClinicalTrials.govBethesda (MD)National Library of Medicine (US)Accessed September 17, 2011
   Google Scholar
• SpiraAIIannottiNOSavinMAA phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small- cell lung cancerClin Lung Cancer2011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• QuinnDIAparicioATsao-WeiDDPhase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC) – Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial [abstract]J Clin Oncol201028:15sSuppl Abst 4539
   Google Scholar
• SchoffskiPRay-CoquardILCioffiAActivity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesLancet Oncol2011121045105221937277
   PubMed Web of Science ®Google Scholar